Kymera Therapeutics Second Quarter 2025 Earnings: Misses Expectations

Kymera Therapeutics (NASDAQ:KYMR) Second Quarter 2025 Results

Key Financial Results

Revenue: US$11.5m (down 55% from 2Q 2024). Net loss: US$76.6m (loss widened by 82% from 2Q 2024). US$0.95 loss per share (further deteriorated from US$0.58 loss in 2Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.NasdaqGM:KYMR Earnings and Revenue Growth August 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kymera Therapeutics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 53%. Earnings per share (EPS) also missed analyst estimates by 16%.

Looking ahead, revenue is expected to decline by 5.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 19%.

Performance of the American Biotechs industry.

The company's shares are down 7.2% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for Kymera Therapeutics (1 is significant!) that you should be aware of.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments